苏州近岸蛋白质科技股份有限公司 2023 年度内部控制评价报告 苏州近岸蛋白质科技股份有限公司全体股东： 公司代码：688137 公司简称：近岸蛋白 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 苏州近岸蛋白质科技股份有限公司（以下简称"公司"或"本公司"）董事会及全体董事保证本报 告内容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带责任。 建立健全并有效实施内部控制是公司董事会的责任。监事会对董事会建立与实施内部控制进行监督， 公司经理层负责组织领导公司内部控制的日常运行。 公司内部控制的目标是：合理保证经营合法合规、资产安全、财务报告及相关信息真实完整，提高 经营效率和效果，促进实现公司的发展战略。 内部控制存在固有局限性，所以仅能对达到上述目标提供合理保证，且内部控制的有效性亦可能随 公司内、外部环境及经营情 ...

民生证券股份有限公司 关于苏州近岸蛋白质科技股份有限公司 民生证券股份有限公司（以下简称"民生证券"或"保荐机构"）作为苏州近岸 蛋白质科技股份有限公司（以下简称"近岸蛋白"或"公司"）首次公开发行股票并 在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》、《上海证 券交易所上市公司自律监管指引第 11 号—持续督导》、《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求（2022 年修订）》、《上海证券 交易所科创板股票上市规则》、《上海证券交易所上市公司自律监管指引第 1 号—规范运作》等有关规定，对近岸蛋白 2023 年度募集资金的存放和实际使用 情况进行了专项核查，核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意苏州近岸蛋白质科技股份有限公司首 次公开发行股票注册的批复》证监许可[2022]1626 号文件核准，公司向社会公开 发行人民币普通股（A 股）1,754.3860 万股，每股发行价为 106.19 元，应募集资 金总额为人民币 186,298.25 万元，根据有关规定扣除发行费用 12,078.67 万元后， 实际募集资金金额为 174,219 ...

Financial Performance - The company reported a revenue of ¥153,191,370.39 in 2023, a decrease of 42.09% compared to the previous year[23]. - The net profit attributable to shareholders was ¥12,843,572.51, reflecting an 85.84% decline year-over-year[23]. - The basic earnings per share dropped by 88.68% to ¥0.18[24]. - The company achieved operating revenue of 153.19 million RMB, a year-on-year decrease of 42.09%[36]. - The net profit attributable to the parent company was 12.84 million RMB, down 85.84% year-on-year[36]. - The company reported a significant decline in pandemic-related business, impacting overall revenue[36]. - The company reported a total revenue of 153,049,843.00, with a gross profit margin of 75.69%, reflecting a decrease of 42.10% year-over-year[177]. - The revenue from mRNA vaccine products decreased by 64.07%[176]. - The gross profit margin for the recombinant antibody segment was 85.74%, but revenue decreased by 47.02% year-over-year due to changes in global demand for pandemic-related products[176]. Dividend and Share Capital - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling RMB 35,087,719.50, which represents 273.19% of the net profit attributable to shareholders for 2023[5]. - As of December 31, 2023, the total share capital is 70,175,439 shares, with the undistributed profits accounting for 26.99% of the parent company's financial statements and 23.47% of the consolidated financial statements[5]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2023 fiscal year[5]. Research and Development - The R&D expenditure as a percentage of revenue rose to 29.24%, an increase of 13.70 percentage points from the previous year[24]. - R&D expenses amounted to 44.79 million RMB, reflecting the company's commitment to innovation despite market challenges[38]. - The total R&D investment reached approximately ¥44.79 million, representing an 8.97% increase from the previous year, with R&D expenses accounting for 29.24% of total revenue[136]. - The company has developed over 200 target protein products, including popular and emerging targets, to meet various drug development needs[121]. - The company has developed various in vitro transcription enzymes and reagents to meet the production needs of different types of RNA projects, including self-replicating RNA and circular RNA[150]. Market and Growth Strategy - The company provided guidance for the next fiscal year, projecting revenue growth of 25% and aiming for $1.875 billion[11]. - The company is expanding its market presence in Asia, targeting a 30% market share in the region by 2025[11]. - The company is actively expanding its product offerings in the mRNA vaccine sector and has filed multiple invention patents[150]. - The company aims to address the "bottleneck" issues in basic biopharmaceutical raw materials, aligning with national strategies for high-quality development in the pharmaceutical industry[46]. - The company is investing $100 million in new technology development to improve its protein expression systems[11]. Operational Efficiency - The company reported a 10% reduction in operational costs due to improved efficiency measures[11]. - The company has focused on enhancing its core competencies in recombinant proteins during the reporting period[26]. - The company maintained a high inventory level, with over 3,300 target and factor protein products, which poses a risk of inventory impairment[165]. - The company has strengthened its internal control system and optimized its management structure to improve operational efficiency[42]. Customer and Market Engagement - User data showed a 15% increase in active users, reaching 2 million by the end of the year[12]. - The sales team increased by 39.33%, enhancing customer coverage and demand exploration, while the total number of employees decreased by 15.97% to 579[42]. - The company participated in over 50 domestic and international conferences and online forums to enhance brand awareness and customer interaction[41]. Risks and Challenges - The report includes a risk statement regarding forward-looking statements, indicating that future plans and strategies do not constitute a commitment to investors[6]. - The company faces risks related to talent retention in the competitive recombinant protein industry, which could impact its competitive position[161]. - The mRNA vaccine and drug industry is still in its early development stage, presenting uncertainties in commercialization[167]. - Changes in tax incentives and government subsidies could adversely affect the company's financial performance if policies are adjusted[166]. Product Development and Innovation - The company launched innovative raw materials for mRNA vaccines, including ultra-low dsRNA T7 RNA polymerase, and introduced a one-tube IVT capping method[45]. - The company has developed a comprehensive technology platform consisting of 23 core technologies, enhancing its competitive advantage and customer service capabilities[100]. - The company has developed multiple innovative mRNA-related products, with increasing demand expected as more vaccine pipelines progress towards commercialization[94]. - The company has established a platform for mRNA design and development, which is expected to be widely used in drug and vaccine development[138]. Financial Health - The net cash flow from operating activities increased by 1,948.16% to ¥69,159,022.07, primarily due to reduced tax payments[26]. - The company has seen over 50% year-on-year growth in conventional diagnostic antibody sales in 2023, despite a decline in COVID-19 diagnostic antibody sales[89]. - The company has experienced a decline in revenue from enzyme and reagent products, with costs decreasing in tandem[184]. - The total procurement from the top five suppliers was 21.73 million RMB, accounting for 20.77% of the total annual procurement[187].

证券代码：688137 证券简称：近岸蛋白 公告编号：2024-015 苏州近岸蛋白质科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：容诚会计师事务所（特殊普通合伙） （以下简称"容诚"） 1、基本信息 容诚会计师事务所（特殊普通合伙）由原华普天健会计师事务所（特殊普通 合伙）更名而来，初始成立于 1988 年 8 月，2013 年 12 月 10 日改制为特殊普通 合伙企业，是国内最早获准从事证券服务业务的会计师事务所之一，长期从事证 券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢外经贸大厦 901- 22 至 901-26，首席合伙人肖厚发。 2、人员信息 截至 2023 年 12 月 31 日，容诚会计师事务所共有合伙人 179 人，共有注册 会计师 1395 人，其中 745 人签署过证券服务业务审计报告。 3、业务规模 容诚会计师事务所经审计的 2022 年度收入总额为 266,287.74 万元，其中审 计 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2024-016 公司董事、监事及高级管理人员。 二、适用期限 2024 年 1 月 1 日至 2024 年 12 月 31 日 三、薪酬标准 苏州近岸蛋白质科技股份有限公司 关于 2024 年度董事、监事、高级管理人员薪酬公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开了第二届董事会第二次会议、第二届监事会第二次会议，分别审议通过《关 于 2024 年度董事薪酬方案的议案》、《关于 2024 年度高级管理人员薪酬方案的 议案》、《关于 2024 年度监事薪酬方案的议案》。关联董事对《关于 2024 年度 董事薪酬方案的议案》、《关于 2024 年度高级管理人员薪酬方案的议案》进行 回避表决，《关于 2024 年度董事薪酬方案的议案》直接提交公司 2023 年年度股 东大会审议。关联监事对《关于 2024 年度监事薪酬方案的议案》进行回避表决， 该议案直接提交公 ...

苏州近岸蛋白质科技股份有限公司 2023 年度会计师事务所的履职情况评估报告及审计委员会履行 监督职责情况报告 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《国有企业、 上市公司选聘会计师事务所管理办法》和《上海证券交易所科创板上市公司自律 监管指引第1 号 -- 规范运作》等相关规范性文件的规定,以及苏州近岸蛋白质 科技股份有限公司(以下简称"公司")《董事会审计委员会工作细则》的有关 规定,现将公司 2023 年度会计师事务所的履职情况评估报告及审计委员会履行 监督职责情况报告汇报如下: 一、会计师事务所的基本情况 容诚会计师事务所(特殊普通合伙)由原华普天健会计师事务所(特殊普通 合伙)更名而来,初始成立于 1988年8月,2013年 12月 10 日改制为特殊普通 合伙企业,是国内最早获准从事证券服务业务的会计师事务所之一,长期从事证 券服务业务。注册地址为北京市西城区阜成门外大街 22 号 1 幢外经贸大厦 901- 22至 901-26,首席合伙人肖厚发。 二、2023年度会计师事务所的履职情况评估报告 按照《审计业务约定书》,遵循《中国注册会计师审计准则》和其他执业规 范,结合公司 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 26,087,054.66, representing a decrease of 39.34% compared to the same period last year[9]. - The net profit attributable to shareholders was a loss of CNY 2,630,474.68, a decline of 123.61% year-over-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 11,706,041.48, down 273.62% from the previous year[9]. - Total operating revenue for Q1 2024 was CNY 26,087,054.66, a decrease of 39.2% compared to CNY 43,002,533.69 in Q1 2023[19]. - Net profit for Q1 2024 was a loss of CNY 2,630,474.68, compared to a profit of CNY 11,141,255.79 in Q1 2023[20]. - In Q1 2024, the company reported a total comprehensive income of -2,647,658.46 CNY, a significant decrease from 11,137,303.03 CNY in Q1 2023[21]. - The basic and diluted earnings per share for Q1 2024 were both -0.04 CNY, compared to 0.16 CNY in Q1 2023[21]. Cash Flow and Liquidity - The net cash flow from operating activities was CNY 7,558,148.81, a decline of 68.17% compared to the same period last year[8]. - Cash inflows from operating activities totaled 56,919,605.96 CNY in Q1 2024, down 26.8% from 77,756,134.69 CNY in Q1 2023[22]. - The total cash outflow from operating activities was 49,361,457.15 CNY, compared to 54,012,021.66 CNY in the previous year[24]. - The company’s cash and cash equivalents at the end of Q1 2024 were 1,392,721,519.76 CNY, compared to 1,485,658,036.01 CNY at the end of Q1 2023[25]. - The company paid 28,597,863.67 CNY to employees in Q1 2024, a slight increase from 27,768,702.82 CNY in Q1 2023[24]. - The company’s cash and cash equivalents as of March 31, 2024, amount to ¥1,393,411,953.22, an increase from ¥863,702,581.67 on December 31, 2023[15]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,310,126,014.98, reflecting a slight increase of 0.49% from the end of the previous year[5]. - Total assets as of Q1 2024 amounted to CNY 2,310,126,014.98, an increase from CNY 2,298,915,220.36 in the previous year[18]. - Total liabilities for Q1 2024 were CNY 121,058,435.51, up from CNY 110,425,722.31 in Q1 2023[17]. - The company's total equity as of Q1 2024 was CNY 2,189,067,579.47, slightly up from CNY 2,188,489,498.05 in the previous year[18]. Research and Development - Research and development expenses totaled CNY 11,000,774.78, accounting for 42.17% of revenue, an increase of 16.57 percentage points year-over-year[5]. - Research and development expenses for Q1 2024 were CNY 11,000,774.78, slightly down from CNY 11,008,017.25 in Q1 2023[20]. - The company is actively pursuing new technologies and products in mRNA vaccines, biopharmaceuticals, and life sciences research[9]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,641[11]. - The largest shareholder, Shanghai Xinbainuo Biotechnology Co., Ltd., holds 30,355,000 shares, accounting for 43.26% of total shares[11]. - The second-largest shareholder, Wujiang Dongyun Venture Capital Co., Ltd., holds 10,120,000 shares, representing 14.42% of total shares[11]. - The total number of shares held by the top ten shareholders includes significant stakes from various investment partnerships[12]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[13]. - The company has not disclosed any related party transactions among the top shareholders[13]. - The company’s actual controller is Zhu Huaxing, who indirectly holds shares through several investment entities[13]. Operational Challenges - The company faced challenges due to a phase adjustment in the domestic biopharmaceutical market and a slowdown in conventional business growth[9]. - The report does not indicate any significant operational changes or new strategies during the reporting period[14]. Marketing and Sales - The company expanded its marketing team and increased sales expenses to enhance business development and brand building[9]. - The company reported a significant increase in sales expenses, which reached CNY 11,402,508.31, compared to CNY 8,499,041.02 in Q1 2023[20].

苏州近岸蛋白质科技股份有限公司 关于 2023 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 经容诚会计师事务所（特殊普通合伙）审计，截至 2023 年 12 月 31 日，苏 州近岸蛋白质科技股份有限公司（以下简称"公司"）2023 年度合并报表实现 归属于上市公司股东的净利润为人民币 12,843,572.51 元，公司 2023 年末母公 司可供分配利润为人民币 129,984,581.35 元。经公司第二届董事会第二次会议 审议，公司 2023 年度拟以实施权益分派股权登记日登记的总股本为基数分配利 润，具体分配方案如下： 证券代码：688137 证券简称：近岸蛋白 公告编号：2024-014 三、公司履行的决策程序 公司拟向全体股东每 10 股派发现金红利人民币 5.00 元（含税）。截至 2023 年 12 月 31 日，公司总股本 7,017.5439 万股，以此计算合计拟派发现金红利 35,087,719.50 元(含税)，占公司 2023 年 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2024 - 018 （二）本次会计政策变更后采用的会计政策 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次会计政策变更系根据中华人民共和国财政部（以下简称"财政部"）发 布的《关于印发<企业会计准则解释第16号>的通知》（财会〔2022〕31号）（ 以下简称"《准则解释第16号》"）变更相应的会计政策，无需提交苏州近岸 蛋白质科技股份有限公司（以下简称"公司"）董事会和股东大会审议。 本次会计政策变更不会对公司财务状况、经营成果和现金流量产生重大影响。 2022年11月30日，财政部颁布了《企业会计准则解释第16号》，其中"关于 单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理" 的规定自2023年1月1日起施行。 根据上述通知要求，公司对现行的会计政策进行相应变更，并按该规定的 生效日期执行。本次会计政策变更是公司按照国家统一的会计制度要求进行的变 更，无需提交公司董事会和股东大会审议。 （一）本次会计政策变更前采用的会计政策 本次会计政策 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2024-011 苏州近岸蛋白质科技股份有限公司 关于换届选举完成暨选举董事长、董事会专门委员 会、监事会主席及聘任高级管理人员、证券事务代 表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州近岸蛋白质科技股份有限公司（以下简称或"公司"）第一届董事会、 监事会任期已经届满，根据《中华人民共和国公司法》（以下简称"《公司法》"） 《上海证券交易所科创板股票上市规则》等法律、法规以及《公司章程》等相关 规定，现将相关情况公告如下： 一、董事会换届选举情况 公司于 2024 年 4 月 23 日召开的 2024 年第一次临时股东大会审议通过了 《关于选举第二届董事会非独立董事的议案》、《关于选举第二届董事会独立 董事的议案》，选举朱化星、赵玉剑、王笃强、王英明、陆幼辰、邹方平为公 司第二届董事会非独立董事；选举宋夏云、张宗新、金坚为公司第二届董事会 独立董事，公司独立董事均已取得独立董事资格证书，且已经上海证券交易所 审核无异议。公司第二届董事会任期自公司 20 ...